Pelatihan Penggunaan Alat Ukur Dasar Bagi Siswa Kelas X SMA IT Al Fahmi Palu

Ilmu Fisika tidaklah terlepas dari kegiatan eksperimen yakni pengamatan dan pengukuran. Hal ini bertujuan untuk menambah pengetahuan serta keterampilan dalam memahami ilmu Fisika dan juga untuk mendukung capaian dari kurikulum yang berlaku. Siswa kelas X sekolah tingkat menengah telah dibekali pembelajaran ilmu Fisika secara teori mengenai pengukuran. Peningkatan pemahaman mengenai pengukuran sebaiknya dilakukan kegiatan pengukuran secara langsung menggunakan beberapa alat ukur dasar yaitu jangka sorong, mikrometer sekrup, dan neraca o’haus. Kegiatan ini dilakukan dengan metode pendekatan saintifik yakni pelaksanaan pengabdian mengandung unsur pengetahuan di bidang keilmuan Fisika. Sebanyak 45 orang peserta mengikuti kegiatan ini yang berasal dari SMA IT AL Fahmi Palu. Hasil dari kegiatan ini menunjukkan adanya peningkatan pemahaman dan keterampilan siswa dalam penggunaan alat ukur dasar berdasarkan keberhasilan siswa melakukan pengukuran secara mandiri. Hal ini dibuktikan dengan hasil penilaian yang diperoleh rata-rata 92,7 yang menunjukkan kriteria sangat baik

Amenable epigenetic traits of dental pulp stem cells underlie high capability of xeno-free episomal reprogramming

Background: While a shift towards non-viral and animal component-free methods of generating induced pluripotent stem (iPS) cells is preferred for safer clinical applications, there is still a shortage of reliable cell sources and protocols for efficient reprogramming. Methods: Here, we show a robust episomal and xeno-free reprogramming strategy for human iPS generation from dental pulp stem cells (DPSCs) which renders good efficiency (0.19%) over a short time frame (13-18 days). Results: The robustness of DPSCs as starting cells for iPS induction is found due to their exceptional inherent stemness properties, developmental origin from neural crest cells, specification for tissue commitment, and differentiation capability. To investigate the epigenetic basis for the high reprogramming efficiency of DPSCs, we performed genome-wide DNA methylation analysis and found that the epigenetic signature of DPSCs associated with pluripotent, developmental, and ecto-mesenchymal genes is relatively close to that of iPS and embryonic stem (ES) cells. Among these genes, it is found that overexpression of PAX9 and knockdown of HERV-FRD improved the efficiencies of iPS generation. Conclusion: In conclusion, our study provides underlying epigenetic mechanisms that establish a robust platform for efficient generation of iPS cells from DPSCs, facilitating industrial and clinical use of iPS technology for therapeutic needs

Investigations on the effect of 2-[(furan-3ylmethylene)-amino]-benzenethiol on corrosion in carbon steel

A Schiff base namely, 2-[(furan-3ylmethylene)-amino]-benzenethiol (2-FAB) was synthesized and its influence on the inhibition of corrosion in carbon steel immersed in 0.5 M H2SO4 was investigated by weight loss analysis, potentiodynamic polarization studies, electrochemical impedance spectroscopy (EIS), scanning electron microscopy (SEM), atomic force microscopy (AFM) and FT-IR spectroscopy. The weight loss measurements showed that 2-FAB has an excellent inhibiting efficiency of 95.51% at a concentration of 250 ppm. The inhibitor efficiency was found to depend on both the concentration and molecular structure of the inhibitor. Potentiodynamic polarization curves revealed that the studied inhibitors represent a mixed-type, predominantly cathodic control. An equivalent circuit is suggested based on an analysis of EIS data. Surface analysis using scanning electron microscope (SEM) and atomic force microscopy (AFM) show a significant morphological improvement on the mild steel surface with the addition of 2-FAB. The negative value of standard free energy of adsorption in the presence of inhibitor suggests the spontaneous adsorption of inhibitors on the carbon steel surface. The Temkin and Langmuir adsorption isotherms were found to provide a accurate description of the adsorption behavior of the inhibitor. Taken as a whole, this work demonstrates that 2-FAB shows promising results in resisting the deterioration of carbon steel in 0.5 M H2SO4 environment. The inhibitor forms a protective film on the surface of the carbon steel, significantly reducing its corrosion rate

Investigation on the corrosion inhibition efficiency of 2, 4-diphenyl-3-aza bicyclo[3.3.1] nonan-9-one in carbon steel immersed in acidic media

The current research investigates the corrosion resistant efficiency of 2,4-diphenyl-3-azabicyclo[3.3.1] nonan – 9–one (PABN) as inhibitor in carbon steel in 0.5 M H2SO4 environment through experimental and theoretical approaches. The weight loss methodology demonstrates that 0.10 ppm of nonan-9-one compound effectively inhibits corrosion in carbon steel submerged in an acidic environment with an efficiency of inhibition as high as 97.2 %. The polarization studies reveals the function of the compound as an inhibitor at the anodic site, influencing the kinetics of carbon steel corrosion effectively. Impedance spectra under alternating current conditions elucidate the influence of the protective film formed by the action of PABN compound on the electrical behavior and corrosion resistance in carbon steel material. This existence of the protective film composed of carbon steel and PABN compound is affirmed through different techniques such as SEM, EDX and AFM. The DFT analysis anticipates the interaction patterns of the inhibitor with the surface of carbon steel using quantum chemical calculations, analyzing the molecular interactions between the molecules of the inhibitor and the surface of carbon steel, providing insights into PABN's corrosion inhibitory properties

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Background and aims: Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different countries. Methods: Lead Investigators from countries formally involved in the EAS FHSC by mid-May 2018 were invited to provide a brief report on FH status in their countries, including available information, programmes, initiatives, and management. Results: 63 countries provided reports. Data on FH prevalence are lacking in most countries. Where available, data tend to align with recent estimates, suggesting a higher frequency than that traditionally considered. Low rates of FH detection are reported across all regions. National registries and education programmes to improve FH awareness/knowledge are a recognised priority, but funding is often lacking. In most countries, diagnosis primarily relies on the Dutch Lipid Clinics Network criteria. Although available in many countries, genetic testing is not widely implemented (frequent cost issues). There are only a few national official government programmes for FH. Under-treatment is an issue. FH therapy is not universally reimbursed. PCSK9-inhibitors are available in ∼2/3 countries. Lipoprotein-apheresis is offered in ∼60% countries, although access is limited. Conclusions: FH is a recognised public health concern. Management varies widely across countries, with overall suboptimal identification and under-treatment. Efforts and initiatives to improve FH knowledge and management are underway, including development of national registries, but support, particularly from health authorities, and better funding are greatly needed. © 2018 Elsevier B.V

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Background and aims: Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different countries. Methods: Lead Investigators from countries formally involved in the EAS FHSC by mid-May 2018 were invited to provide a brief report on FH status in their countries, including available information, programmes, initiatives, and management. Results: 63 countries provided reports. Data on FH prevalence are lacking in most countries. Where available, data tend to align with recent estimates, suggesting a higher frequency than that traditionally considered. Low rates of FH detection are reported across all regions. National registries and education programmes to improve FH awareness/knowledge are a recognised priority, but funding is often lacking. In most countries, diagnosis primarily relies on the Dutch Lipid Clinics Network criteria. Although available in many countries, genetic testing is not widely implemented (frequent cost issues). There are only a few national official government programmes for FH. Under-treatment is an issue. FH therapy is not universally reimbursed. PCSK9-inhibitors are available in ∼2/3 countries. Lipoprotein-apheresis is offered in ∼60 countries, although access is limited. Conclusions: FH is a recognised public health concern. Management varies widely across countries, with overall suboptimal identification and under-treatment. Efforts and initiatives to improve FH knowledge and management are underway, including development of national registries, but support, particularly from health authorities, and better funding are greatly needed. © 2018 Elsevier B.V

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Background The European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration (FHSC) global registry provides a platform for the global surveillance of familial hypercholesterolaemia through harmonisation and pooling of multinational data. In this study, we aimed to characterise the adult population with heterozygous familial hypercholesterolaemia and described how it is detected and managed globally. Methods Using FHSC global registry data, we did a cross-sectional assessment of adults (aged 18 years or older) with a clinical or genetic diagnosis of probable or definite heterozygous familial hypercholesterolaemia at the time they were entered into the registries. Data were assessed overall and by WHO regions, sex, and index versus non-index cases. Findings Of the 61 612 individuals in the registry, 42 167 adults (21 999 [53·6%] women) from 56 countries were included in the study. Of these, 31 798 (75·4%) were diagnosed with the Dutch Lipid Clinic Network criteria, and 35 490 (84·2%) were from the WHO region of Europe. Median age of participants at entry in the registry was 46·2 years (IQR 34·3–58·0); median age at diagnosis of familial hypercholesterolaemia was 44·4 years (32·5–56·5), with 40·2% of participants younger than 40 years when diagnosed. Prevalence of cardiovascular risk factors increased progressively with age and varied by WHO region. Prevalence of coronary disease was 17·4% (2·1% for stroke and 5·2% for peripheral artery disease), increasing with concentrations of untreated LDL cholesterol, and was about two times lower in women than in men. Among patients receiving lipid-lowering medications, 16 803 (81·1%) were receiving statins and 3691 (21·2%) were on combination therapy, with greater use of more potent lipid-lowering medication in men than in women. Median LDL cholesterol was 5·43 mmol/L (IQR 4·32–6·72) among patients not taking lipid-lowering medications and 4·23 mmol/L (3·20–5·66) among those taking them. Among patients taking lipid-lowering medications, 2·7% had LDL cholesterol lower than 1·8 mmol/L; the use of combination therapy, particularly with three drugs and with proprotein convertase subtilisin–kexin type 9 inhibitors, was associated with a higher proportion and greater odds of having LDL cholesterol lower than 1·8 mmol/L. Compared with index cases, patients who were non-index cases were younger, with lower LDL cholesterol and lower prevalence of cardiovascular risk factors and cardiovascular diseases (all p<0·001). Interpretation Familial hypercholesterolaemia is diagnosed late. Guideline-recommended LDL cholesterol concentrations are infrequently achieved with single-drug therapy. Cardiovascular risk factors and presence of coronary disease were lower among non-index cases, who were diagnosed earlier. Earlier detection and greater use of combination therapies are required to reduce the global burden of familial hypercholesterolaemia. Funding Pfizer, Amgen, Merck Sharp & Dohme, Sanofi–Aventis, Daiichi Sankyo, and Regeneron